We have changed our name from Cure Our Ovarian Cancer to the Ovarian Cancer Foundation NZ » Read More

research we fund

Funding transformational research to find tomorrow’s cure

magnifying glass icon

The survival rate of ovarian cancer is less than half that of breast cancer or prostate cancer. Quite simply, the treatments women need do not exist yet. Research is key to finding them.

OCFNZ is committed to funding research and working towards a future where every woman can live the life she wants, free from ovarian cancer.

Research grants

Ovarian cancer is one of the least researched cancers in New Zealand, and most years, ovarian cancer research receives no government support. We’re here to change that. 

To further research in the ovarian cancer field each year, we hold a competitive research grants round, and researchers from across New Zealand submit their best ideas to improve ovarian cancer survival. Applications are ranked by expert researchers, with the highest-scoring applications receiving funding. We continue to be impressed by the quality of applications we receive for these grants.

The research we fund is crucial to improve women’s survival, yet we often have to turn down promising projects due to limited funding. We’re grateful to our community for continuing to donate and fundraise to make research like the below projects possible.

OCFNZ acknowledges the support of the gynaecological cancer research charity Graci Foundation who share their expertise, administering our grants application process.

Research projects we've funded

2023

Investigating chemotherapeutic response in ovarian cancer: generating tumour organoids for wahine Maori patients

Helena Abolins-Thompson (Ngati Toa Rangatira; Kai Tahu), PhD Candidate, Department of Surgery and Anaesthesia, University of Otago, Wellington

Validating drug combination efficacy in low-grade serous ovarian cancer using a chicken embryo model

Dr Kenny Chitcholtan, Senior Research Fellow, Department of Obstetrics and Gynaecology, University of Otago, Christchurch

2022

Targeted Molecular Profiling of High-Grade Serous/Endometrioid Ovarian Cancer

Dr. Magdalena Ratajska, Research Fellow, Department of Pathology, University of Otago, Dunedin

Combination of re-purposed iron-chelating and anti-malarial drugs to overcome autophagy cell survival in serous ovarian cancer

Dr Kenny Chitcholtan, Senior Research Fellow, Department of Obstetrics and Gynaecology, University of Otago, Christchurch

Investigation of dual targeting in low-grade serous ovarian cancer

Dr Makhdoom Sarwar, Postdoctoral Research Fellow, Gynaecologic Oncology, University of Otago, Christchurch

2021

Using proteomic phosphopeptides to predict the efficacy of drug combination in a trametinib-resistant low-grade ovarian cancer in 3D cell model

Dr Kenny Chitcholtan, Senior Research Fellow, Department of Obstetrics and Gynaecology, University of Otago, Christchurch

2020

Correlating molecular alterations in low-grade serous carcinoma (LGSC) to patient outcomes in New Zealand

Dr Makhdoom Sarwar, Postdoctoral Research Fellow, Gynaecologic Oncology, University of Otago, Christchurch

2019

Identifying a combination therapy likely to be of therapeutic benefit in low-grade serous ovarian cancer

Dr Kenny Chitcholtan, Senior Research Fellow, Department of Obstetrics and Gynaecology, University of Otago, Christchurch